Skip to main content

Nasolabial Fold Wrinkles

2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
2
DL6049Phase 31 trial
DL6049Phase 31 trial
Active Trials
NCT00444210Completed240Est. Apr 2006
NCT00444353Completed240Est. Jan 2007
Panion & BF Biotech
Panion & BF BiotechTaiwan - Taipei City
1 program
PBF PLLA microsphereN/A1 trial
Active Trials
NCT06013332Active Not Recruiting50Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthDL6049
Bausch HealthDL6049
Panion & BF BiotechPBF PLLA microsphere

Clinical Trials (3)

Total enrollment: 530 patients across 3 trials

DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up

Start: Aug 2004Est. completion: Jan 2007240 patients
Phase 3Completed

DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles

Start: Jun 2004Est. completion: Apr 2006240 patients
Phase 3Completed
NCT06013332Panion & BF BiotechPBF PLLA microsphere

Polymeric Microspheres vs Sculptra® in the Treatment of Moderate to Severe Nasolabial Folds

Start: Apr 2024Est. completion: Dec 202550 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.